News | May 17, 2023
Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData
Farxiga is expected to have such a strong influence on the market due to the impressive results
Farxiga is expected to have such a strong influence on the market due to the impressive results
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
